|
1 Indications And Usage Ilaris Is An Interleukin-1β Blocker Indicated For The Treatment Of: Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (Caps), In Adults And Children 4 Years Of Age And Older, Including: Familial Cold Auto-Inflammatory Syndrome (Fcas). ( 1.1 ) Muckle-Wells Syndrome (Mws). ( 1.1 ) Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Traps) In Adult And Pediatric Patients. ( 1.1 ) Hyperimmunoglobulin D Syndrome (Hids)/mevalonate Kinase Deficiency (Mkd) In Adult And Pediatric Patients. ( 1.1 ) Familial Mediterranean Fever (Fmf) In Adult And Pediatric Patients. ( 1.1 ) Active Still’s Disease, Including Adult-Onset Still’s Disease (Aosd) And Systemic Juvenile Idiopathic Arthritis (Sjia) In Patients Aged 2 Years And Older. ( 1.2 ) 1.1 Periodic Fever Syndromes Ilaris ® (Canakinumab) Is An Interleukin-1β (Il-1 Β) Blocker Indicated For The Treatment Of The Following Autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (Caps) Ilaris Is Indicated For The Treatment Of Cryopyrin-Associated Periodic Syndromes (Caps), In Adults And Children 4 Years Of Age And Older, Including: Familial Cold Autoinflammatory Syndrome (Fcas) Muckle-Wells Syndrome (Mws) Tumor Necrosis Factor Receptor (Tnf) Associated Periodic Syndrome (Traps) Ilaris Is Indicated For The Treatment Of Tumor Necrosis Factor (Tnf) Receptor Associated Periodic Syndrome (Traps) In Adult And Pediatric Patients. Hyperimmunoglobulin D Syndrome (Hids)/mevalonate Kinase Deficiency (Mkd) Ilaris Is Indicated For The Treatment Of Hyperimmunoglobulin D (Hyper-Igd) Syndrome (Hids)/mevalonate Kinase Deficiency (Mkd) In Adult And Pediatric Patients. Familial Mediterranean Fever (Fmf) Ilaris Is Indicated For The Treatment Of Familial Mediterranean Fever (Fmf) In Adult And Pediatric Patients. 1.2 Still’s Disease (Adult-Onset Still’s Disease [Aosd] And Systemic Juvenile Idiopathic Arthritis [Sjia]) Ilaris Is Indicated For The Treatment Of Active Still’s Disease, Including Adult-Onset Still’s Disease (Aosd) And Systemic Juvenile Idiopathic Arthritis (Sjia) In Patients Aged 2 Years And Older.
|